Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    xenikos
Previous Study | Return to List | Next Study

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (2002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04934670
Recruitment Status : Recruiting
First Posted : June 22, 2021
Last Update Posted : August 2, 2022
Sponsor:
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
Blood and Marrow Transplant Clinical Trials Network
National Cancer Institute (NCI)
National Marrow Donor Program
Information provided by (Responsible Party):
Xenikos

Brief Summary:
This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host Disease (SR-aGVHD). The primary hypothesis is that T-Guard treatment will improve the Day 28 complete response (CR) rate in patients with Grades III and IV SR-aGVHD compared to ruxolitinib.

Condition or disease Intervention/treatment Phase
Steroid-Refractory Acute Graft Versus Host Disease Drug: T-Guard Drug: Ruxolitinib Phase 3

Detailed Description:

Graft-vs-Host Disease (GVHD) is a complication that affects many hematopoietic stem cell transplant (HSCT) patients; it occurs when the new cells from a transplant attack the recipient's body. Acute GVHD (aGVHD) typically develops within the first three months after HSCT and is typically treated with steroid therapy. A significant fraction of the aGVHD population (10-50%) fail to respond to treatment and are deemed steroid-refractory (SR).

Participants that develop Grade III or IV SR aGVHD will be randomized to receive T-Guard or ruxolitinib and will be followed for approximately 180 days. Participants will be stratified by center region (US vs. Europe) and age group (at least 55 years vs. under 55). Participants randomized to the T-Guard arm will receive 4 doses administered intravenously as four 4-hour infusions, and participants randomized to the ruxolitinib arm will receive one dose administered orally twice a day. The primary analysis will include all participants that are randomized.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 246 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be randomized at a ratio of 1:1 between the treatment arms
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare T-Guard to Ruxolitinib for the Treatment of Patients With Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) (BMT CTN 2002)
Actual Study Start Date : June 16, 2022
Estimated Primary Completion Date : June 1, 2025
Estimated Study Completion Date : June 1, 2026


Arm Intervention/treatment
Experimental: T-Guard
Participants will be administered four doses of T-Guard intravenously for a 4-hour period every other day
Drug: T-Guard
T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).

Active Comparator: Ruxolitinib
Participants will take ruxolitinib twice daily for continuous daily dosing
Drug: Ruxolitinib
Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
Other Names:
  • Jakafi
  • Jakavi




Primary Outcome Measures :
  1. Complete Response (CR) [ Time Frame: Day 28 ]
    The primary objective of this trial is to assess the rate of CR on Day 28 post-randomization in Grades III and IV SR-aGVHD patients treated with T-Guard treatment in comparison to ruxolitinib.


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Days 60, 90, and 180 ]
    OS is defined as survival of death from any cause. The time from randomization until death from any cause will be described for each arm.

  2. Duration of Complete Response (DoCR) [ Time Frame: Day 28 ]
    DoCR will be evaluated only in the set of participants who are in CR at Day 28 post-randomization. The primary definition of DoCR is the time from Day 28 until an aGVHD target organ worsens by at least 1 stage and requires a significant escalation in treatment, or death.

  3. Time to Complete Response (CR) [ Time Frame: Days 28 and 56 ]
    The time from randomization until first attaining a CR will be described for each treatment arm, with death and additional systemic treatment for aGVHD treated as competing risks.

  4. Overall Response Rate (ORR) [ Time Frame: Days 14, 28, and 56 ]
    Overall response is defined as either a complete or partial response (CR+PR). The ORR will be estimated for each treatment arm.

  5. Proportion of Response [ Time Frame: Days 6, 14, 28, and 56 ]
    The proportion of participants in each aGVHD response category will be described for each treatment arm.

  6. Non-relapse Mortality (NRM) [ Time Frame: Days 90 and 180 ]
    NRM is defined as death from any cause other than malignancy relapse/progression. The time from randomization until NRM will be described for each treatment arm.

  7. Relapse-free Survival (RFS) [ Time Frame: Day 180 ]
    RFS is defined as being alive and free of malignancy relapse/progression. The time from randomization until malignancy relapse/progression or death will be described for each arm.

  8. GVHD-free Survival [ Time Frame: Days 90 and 180 ]
    GVHD-free survival is defined as being alive, in CR, and free of cGVHD. The proportion of participants with GVHD-free survival post-randomization will be estimated for each treatment arm.

  9. Chronic GVHD (cGVHD) [ Time Frame: Day 180 ]
    The maximum severity of cGVHD post-randomization will be tabulated by arm. The time from randomization until onset of cGVHD of any severity (mild, moderate, or severe) will be described for each treatment arm.

  10. Relapse/Progression of Underlying Malignancy [ Time Frame: Day 180 ]
    The time from randomization until malignancy relapse/progression will be described for each treatment arm, with death prior to relapse/progression treated as a competing risk.

  11. Incidence of Infections [ Time Frame: Day 90 ]
    The frequency of Grade 2-3 infections occurring after randomization will be tabulated by infection site, date of onset, and severity. The cumulative incidence of Grade 2-3 infections will be described by treatment arm.

  12. Incidence of Toxicities [ Time Frame: Day 56 ]
    The frequency of Grade 3-5 toxicities per CTCAE version 5 occurring after randomization will be tabulated by organ system for each treatment arm. The maximum severity of reported toxicities during that period will also be summarized.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To be eligible to participate in this study, patients must meet the following:

  1. Patients must be at least 18.0 years of age at the time of consent.
  2. Patient has undergone first allo-HSCT from any donor source or graft source. Recipients of nonmyeloablative, reduced intensity, and myeloablative conditioning regimens are eligible.
  3. Patients diagnosed with Grade III/IV SR-aGVHD after allo-HSCT. SR includes aGVHD initially treated at a lower steroid dose, but must meet one of the following criteria:

    • Progressed or new organ involvement after 3 days of treatment with methylprednisolone (or equivalent) of greater than or equal to 2 mg/kg/day
    • No improvement after 7 days of primary treatment with methylprednisolone (or equivalent) of greater than or equal to 2mg/kg/day
    • Patients with visceral (GI and/or liver) plus skin aGVHD at methylprednisolone (or equivalent) initiation with improvement in skin GVHD without any improvement in visceral GVHD after 7 days of primary treatment with methylprednisolone (or equivalent) of greater than or equal to 2mg/kg/day
    • Patients who have skin GVHD alone and develop visceral aGVHD during treatment with methylprednisolone (or equivalent) of greater than or equal to 1mg/kg/day and do not improve after 3 days of greater than or equal to 2mg/kg/day Improvement or progression in organs is determined by comparing current organ staging to staging at initiation of methylprednisolone (or equivalent) treatment.
  4. Patients must have evidence of myeloid engraftment (e.g., absolute neutrophil count greater than or equal to 0.5 × 109/L for 3 consecutive days if ablative therapy was previously used). Use of growth factor supplementation is allowed.
  5. Patients or an impartial witness (in case the patient is capable of providing verbal consent but not capable of signing the informed consent form (ICF)) should have given written informed consent.

Exclusion Criteria:

Patients will be excluded from study entry if they meet any of the following exclusion criteria:

  1. Patients who have a creatinine greater than or equal to 2mg/dL or estimated creatinine clearance less than 40 mL/min or those requiring hemodialysis.
  2. Patients who have been diagnosed with active TMA, defined as meeting all the following criteria:

    • Greater than 4% schistocytes in blood (or equivalent if semiquantitative scale is used e.g., 3+ or 4+ schistocytes on peripheral blood smear)
    • De novo, prolonged or progressive thrombocytopenia (platelet count less than 50 x 109/L or 50% or greater reduction from previous counts)
    • Sudden and persistent increase in lactate dehydrogenase concentration greater than 2x ULN
    • Decrease in hemoglobin concentration or increased transfusion requirement attributed to Coombs-negative hemolysis
    • Decrease in serum haptoglobin
  3. Patients who have previously received treatment with eculizumab.
  4. Patients who have previously received checkpoint inhibitors (either before or after allo-HCT).
  5. Patients who have been diagnosed with overlap syndrome, that is, with any concurrent features of cGVHD.
  6. Patients requiring mechanical ventilation or vasopressor support.
  7. Patients who have received any systemic treatment, besides steroids, as upfront treatment of aGVHD or as treatment for SR-aGVHD. Reinstitution of previously used GVHD prophylaxis agents (e.g., tacrolimus, cyclosporin, MTX, MMF) or substitutes in cases with previously documented intolerance will be permitted. Previous treatment with a JAK inhibitor as part of GVHD prophylaxis or treatment is not allowed.
  8. Patients who have severe hypoalbuminemia, with an albumin of less than or equal to 1 g/dl.
  9. Patients who have a creatine kinase (CK) level of greater than 5 times the upper limit of normal.
  10. Patients with uncontrolled infections. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Persisting fever without other signs or symptoms will not be interpreted as progressing infection. Progression of infection is defined as:

    • hemodynamic instability attributable to sepsis OR
    • new symptoms attributable to infection OR
    • worsening physical signs attributable to infection OR
    • worsening radiographic findings attributable to infection Patients with radiographic findings attributable to infection within 4 weeks prior to enrollment must have a repeat radiographic exam within one week of enrollment that documents absence of worsening.
  11. Patients with evidence of relapsed, progressing, or persistent malignancy, or who have been treated for relapse after transplant, or who may require rapid immune suppression withdrawal as pre-emergent treatment of early malignancy relapse.
  12. Patients with evidence of minimal residual disease requiring withdrawal of systemic immune suppression.
  13. Patients with unresolved serious toxicity or complications (other than aGVHD) due to previous transplant.
  14. History of sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD).
  15. Patients with known hypersensitivity to any of the components murine mAb or Recombinant Ricin Toxin A-chain (RTA).
  16. Patients who have had treatment with any other investigational agent, device, or procedure within 21 days (or 5 half-lives, whichever is greater) prior to enrollment. An investigational agent is defined as medications without any known FDA or EMA approved indications.
  17. Patients who have received more than one allo-HSCT.
  18. Patients with known human immunodeficiency virus infection.
  19. Patients who have a BMI greater than or equal to 35 kg/m2.
  20. Patients who are taking sirolimus must discontinue prior to starting study treatment.

    The sirolimus blood level must be less than 2 ng/mL prior to starting study treatment.

  21. Female patients who are pregnant, breast feeding, or, if sexually active and of childbearing potential, unwilling to use effective birth control from start of treatment until 30 days after the last study treatment.
  22. Male patients who are, if sexually active and with a female partner of childbearing potential, unwilling to use effective birth control from start of treatment until 65 days after the last study treatment.
  23. Patients with any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the patient; or interfere with interpretation of study data.
  24. Patients whose decision to participate might be unduly influenced by perceived expectation of gain or harm by participation, such as patients in detention due to official or legal order.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04934670


Contacts
Layout table for location contacts
Contact: Heather Wittsack 301-251-1161 hwittsack@emmes.com
Contact: Adam Mendizabal, PhD amendizabal@emmes.com

Locations
Show Show 51 study locations
Sponsors and Collaborators
Xenikos
National Heart, Lung, and Blood Institute (NHLBI)
Blood and Marrow Transplant Clinical Trials Network
National Cancer Institute (NCI)
National Marrow Donor Program
Investigators
Layout table for investigator information
Study Director: Mary Horowitz, MD, MS Center for International Blood and Marrow Transplant Research
Study Director: Willem Klaasen Xenikos, BV
Additional Information:
Layout table for additonal information
Responsible Party: Xenikos
ClinicalTrials.gov Identifier: NCT04934670    
Other Study ID Numbers: BMT CTN 2002
5U24HL138660-02 ( U.S. NIH Grant/Contract )
2021-000343-53 ( EudraCT Number )
XEN-TG-005 ( Other Identifier: Xenikos, BV )
First Posted: June 22, 2021    Key Record Dates
Last Update Posted: August 2, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Xenikos:
T-Guard
Ruxolitinib
Steroid-Refractory
GVHD
Acute GVHD
aGVHD
Grade III
Grade IV
Complete Response (CR)
Transplant
Hematopoietic Stem Cell Transplant (HSCT)
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases